CA3065661A1 - Cell culture methods - Google Patents

Cell culture methods Download PDF

Info

Publication number
CA3065661A1
CA3065661A1 CA3065661A CA3065661A CA3065661A1 CA 3065661 A1 CA3065661 A1 CA 3065661A1 CA 3065661 A CA3065661 A CA 3065661A CA 3065661 A CA3065661 A CA 3065661A CA 3065661 A1 CA3065661 A1 CA 3065661A1
Authority
CA
Canada
Prior art keywords
cysteine
cystine
recombinant protein
tryptophan
production phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065661A
Other languages
English (en)
French (fr)
Inventor
Bassem BEN YAHIA
Laetitia Malphettes
Nadine KOCHANOWSKI
Gill RENNER
Sandrine DURRAN
Andrew Jeffrey Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3065661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CA3065661A1 publication Critical patent/CA3065661A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3065661A 2017-05-31 2018-05-29 Cell culture methods Pending CA3065661A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1708655.4 2017-05-31
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Publications (1)

Publication Number Publication Date
CA3065661A1 true CA3065661A1 (en) 2018-12-06

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065661A Pending CA3065661A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Country Status (21)

Country Link
US (3) US12077796B2 (cg-RX-API-DMAC10.html)
EP (2) EP3630946B1 (cg-RX-API-DMAC10.html)
JP (3) JP7460370B2 (cg-RX-API-DMAC10.html)
KR (3) KR102975392B1 (cg-RX-API-DMAC10.html)
CN (2) CN110741077B (cg-RX-API-DMAC10.html)
AU (2) AU2018276376C1 (cg-RX-API-DMAC10.html)
BR (1) BR112019024390A2 (cg-RX-API-DMAC10.html)
CA (1) CA3065661A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019003459A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019012871A2 (cg-RX-API-DMAC10.html)
EA (1) EA201992828A1 (cg-RX-API-DMAC10.html)
ES (1) ES2978394T3 (cg-RX-API-DMAC10.html)
GB (1) GB201708655D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20240585T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066922T2 (cg-RX-API-DMAC10.html)
IL (2) IL317828A (cg-RX-API-DMAC10.html)
MX (1) MX2019014140A (cg-RX-API-DMAC10.html)
MY (1) MY193535A (cg-RX-API-DMAC10.html)
PL (1) PL3630946T3 (cg-RX-API-DMAC10.html)
RU (2) RU2758674C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018219968A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN116635416A (zh) * 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
GB202105424D0 (en) * 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
WO2025262319A1 (en) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Modifying blue color formation in bioprocesses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
DE602004027905D1 (de) 2003-05-15 2010-08-12 Wyeth Llc Kontrollierte glukosezufuhr für tierzellkultur
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
MX2009004974A (es) 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
JP5749930B2 (ja) 2008-10-28 2015-07-15 中外製薬株式会社 ペプチド含有動物細胞培養用培地
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CN102858953B (zh) 2010-04-26 2015-09-09 诺瓦提斯公司 改进的细胞培养基
LT2563906T (lt) 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP6265970B2 (ja) 2012-03-26 2018-01-24 サノフイ 安定なIgG4に基づく結合剤の製剤
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CA2903589A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
BR112016027797A2 (pt) 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína
KR20170100074A (ko) 2014-12-29 2017-09-04 완롭 위롯페이싯 상승된 전압 및 향상된 장착 방식을 구비한 엔진 연소시스템의 산소효율 증진장치
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
SG11201809408SA (en) * 2016-04-28 2018-11-29 Merck Patent Gmbh Method for reducing the trisulfide level in proteins
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
AU2018276376B2 (en) 2024-08-15
CN119326882A (zh) 2025-01-21
EP4397682A3 (en) 2024-08-21
US20250051824A1 (en) 2025-02-13
JP2020521490A (ja) 2020-07-27
KR20250156183A (ko) 2025-10-31
JP7560420B2 (ja) 2024-10-02
AU2018276376C1 (en) 2025-01-30
KR20240096888A (ko) 2024-06-26
EP3630946C0 (en) 2024-03-27
RU2021128024A (ru) 2021-12-08
BR112019024390A2 (pt) 2020-07-14
ES2978394T3 (es) 2024-09-11
AU2018276376A1 (en) 2019-12-12
JP7406593B2 (ja) 2023-12-27
IL270880A (en) 2020-01-30
US20250066832A1 (en) 2025-02-27
US20200239923A1 (en) 2020-07-30
CO2019012871A2 (es) 2020-01-17
IL270880B1 (en) 2025-01-01
MY193535A (en) 2022-10-18
RU2019143742A (ru) 2021-06-30
MX2019014140A (es) 2020-02-07
AU2024259881B2 (en) 2025-02-13
RU2758674C2 (ru) 2021-11-01
US12077796B2 (en) 2024-09-03
EP4397682A2 (en) 2024-07-10
JP2021185185A (ja) 2021-12-09
JP7460370B2 (ja) 2024-04-02
KR20200012972A (ko) 2020-02-05
GB201708655D0 (en) 2017-07-12
RU2019143742A3 (cg-RX-API-DMAC10.html) 2021-06-30
KR102975392B1 (ko) 2026-06-09
IL317828A (en) 2025-02-01
IL270880B2 (en) 2025-05-01
JP2022153421A (ja) 2022-10-12
PL3630946T3 (pl) 2024-07-01
CL2019003459A1 (es) 2020-04-24
CN110741077A (zh) 2020-01-31
EP3630946A1 (en) 2020-04-08
HRP20240585T1 (hr) 2024-07-19
EA201992828A1 (ru) 2020-04-21
AU2024259881A1 (en) 2024-11-28
CN110741077B (zh) 2024-10-11
EP3630946B1 (en) 2024-03-27
KR102971905B1 (ko) 2026-06-01
HUE066922T2 (hu) 2024-09-28
WO2018219968A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
US20250051824A1 (en) Cell culture methods
EP3717631B1 (en) Cell culture methods
AU2018264100C1 (en) Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
EA044551B1 (ru) Способы культивирования клеток
US20240425894A1 (en) Cell culture processes
HK40114294A (en) Cell culture methods
BR122024024868A2 (pt) Métodos de cultura celular
KR20250022781A (ko) 세포 배양 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200805

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250507

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250611

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250611

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260507